GT199900039A - Combinaciones de estatina-inhibidor de mmp. - Google Patents

Combinaciones de estatina-inhibidor de mmp.

Info

Publication number
GT199900039A
GT199900039A GT199900039A GT199900039A GT199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A
Authority
GT
Guatemala
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
frague
fleasure
Prior art date
Application number
GT199900039A
Other languages
English (en)
Spanish (es)
Inventor
Roger Schofield Newton
Bruce David Roth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900039A publication Critical patent/GT199900039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT199900039A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp. GT199900039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
GT199900039A true GT199900039A (es) 2000-09-06

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900039A GT199900039A (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp.

Country Status (18)

Country Link
EP (1) EP1063991A1 (enExample)
JP (1) JP2002506818A (enExample)
KR (1) KR20010041916A (enExample)
AR (1) AR018113A1 (enExample)
AU (1) AU1591699A (enExample)
BR (1) BR9815745A (enExample)
CA (1) CA2309588A1 (enExample)
CO (1) CO5070670A1 (enExample)
GT (1) GT199900039A (enExample)
HN (1) HN1999000029A (enExample)
MY (1) MY140504A (enExample)
NZ (1) NZ505994A (enExample)
PA (1) PA8469001A1 (enExample)
PE (1) PE20000348A1 (enExample)
SV (1) SV1999000026A (enExample)
UY (1) UY25436A1 (enExample)
WO (1) WO1999047138A1 (enExample)
ZA (1) ZA992106B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2590278A1 (en) 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
EP1948599A1 (en) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20110182851A1 (en) * 2008-07-11 2011-07-28 Jan Nilsson Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284142B6 (sk) * 1995-11-02 2004-10-05 Warner-Lambert Company Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
JP2002506818A (ja) 2002-03-05
CA2309588A1 (en) 1999-09-23
KR20010041916A (ko) 2001-05-25
MY140504A (en) 2009-12-31
EP1063991A1 (en) 2001-01-03
BR9815745A (pt) 2000-11-14
UY25436A1 (es) 2001-10-25
AU1591699A (en) 1999-10-11
PE20000348A1 (es) 2000-05-22
WO1999047138A1 (en) 1999-09-23
CO5070670A1 (es) 2001-08-28
AR018113A1 (es) 2001-10-31
NZ505994A (en) 2003-10-31
HN1999000029A (es) 1999-09-29
ZA992106B (en) 1999-09-30
PA8469001A1 (es) 2002-09-17
SV1999000026A (es) 2000-01-18

Similar Documents

Publication Publication Date Title
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
BR9812879A (pt) Lente oftálmica
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
EA199800667A1 (ru) Новые фенантридины
PL317425A1 (en) Combinations of retroviral protease inhibitors
EP0934064A4 (en) THROMBIN INHIBITORS
SI1427409T1 (sl) Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
GT199900039A (es) Combinaciones de estatina-inhibidor de mmp.
DE69625230D1 (de) Thrombininhibitoren
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
PT1187612E (pt) Utilizacao do riluzole para o tratamento da esclerose multipla
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
NO20005548D0 (no) Mykobakterieinhibitorer
ATE117549T1 (de) Lysyl-oxidase-inhibitoren.
NO995849D0 (no) Aldehydfritt desinfeksjonsmiddel for overflater og instrumenter
AR034375A1 (es) Combinacion de un inhibidor de ptpasa y un agente de sulfonilurea
BR9612549A (pt) Método para tratamento de agressão excessiva
PT828483E (pt) Utilizacao de derivados de tropolona como inibidores da enzima inositol monofosfatase
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
ECSP951559A (es) Inhibidores de la 5- lipoxigenasa
ECSP992885A (es) Combinaciones de estatina-inhibidor de mmp
IT1304535B1 (it) Protesi vascolari e protesi per accesso vascolare basate su elastomeritermoplastici fluorurati.